Arena's APD125 for insomnia improves sleep in three phase 1 clinical trials

By Lisa Kerner

Charlotte, N.C., June 21 - Arena Pharmaceuticals, Inc. said results from its three phase 1 clinical studies of APD125 for insomnia demonstrated the compound's effectiveness in improving sleep parameters without impairing next-day psychomotor skills or memory.

ADP125, a selective inverse agonist of the 5-HT2A serotonin receptor, also had an excellent safety and tolerability profile.

In all three randomized, double blinded and placebo controlled trials, ADP125 showed improvements in deep sleep, sleep continuity, sleep architecture and continuous bouts of sleep at doses from 10 mg to 40 mg.

"We believe APD125 merits further evaluation as a novel therapy to promote sleep maintenance, and we look forward to initiating a phase 2 clinical trial of APD125 in patients with chronic insomnia," president and chief executive officer Jack Lief said in a company news release.

Study data from three clinical trials (APD125-001, APD125-002 and APD125-003) was presented at the 20th Anniversary Meeting of the Associated Professional Sleep Societies in Salt Lake City.

San Diego-based Arena is a clinical-stage biopharmaceutical company specializing in small molecule drugs for metabolic, central nervous system, cardiovascular and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.